South Korean biopharma firm Celltrion aborts merger with affiliate Celltrion Pharm due to shareholder opposition.

South Korean biopharma firm Celltrion abandons merger plan with affiliate Celltrion Pharm due to shareholder disagreements; 36.2% opposed, 55.1% abstained, and only 8.7% supported the merger. Despite majority approval from Celltrion Pharm shareholders, lack of support led to the decision. Celltrion aimed to become a global drugmaker in biosimilars and new drug development through mergers.

August 16, 2024
4 Articles